POU5F1 and pancreatic neoplasm: An experiment has shown that BBR (15 μM) reduces expression levels of SOX2, Nanog and POU5F1 as CSC markers to impair resistance of pancreatic cancer cells to gemcitabine and suppress their progression [389].